Jennifer Lynn Irani, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Digestive System Surgical Procedures | 5 | 2022 | 569 | 1.520 |
Why?
|
Anus Neoplasms | 4 | 2021 | 295 | 0.590 |
Why?
|
Judgment | 1 | 2018 | 288 | 0.570 |
Why?
|
Rectal Neoplasms | 5 | 2021 | 1125 | 0.520 |
Why?
|
Enterostomy | 1 | 2013 | 15 | 0.490 |
Why?
|
Surgical Stomas | 1 | 2013 | 45 | 0.470 |
Why?
|
Appendectomy | 3 | 2019 | 387 | 0.440 |
Why?
|
Urethral Stricture | 1 | 2011 | 58 | 0.430 |
Why?
|
General Surgery | 5 | 2015 | 1645 | 0.430 |
Why?
|
Competency-Based Education | 2 | 2010 | 234 | 0.410 |
Why?
|
Androgen Antagonists | 1 | 2019 | 1283 | 0.400 |
Why?
|
Survival Rate | 24 | 2021 | 13255 | 0.400 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2019 | 1544 | 0.400 |
Why?
|
Perineum | 3 | 2019 | 202 | 0.390 |
Why?
|
Dilatation | 1 | 2011 | 265 | 0.390 |
Why?
|
Renal Insufficiency | 2 | 2012 | 804 | 0.370 |
Why?
|
Urethra | 1 | 2011 | 409 | 0.360 |
Why?
|
Neoplasm Staging | 20 | 2021 | 11192 | 0.360 |
Why?
|
Rectum | 3 | 2022 | 887 | 0.350 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2020 | 8925 | 0.350 |
Why?
|
Testosterone | 1 | 2019 | 2359 | 0.340 |
Why?
|
Appendiceal Neoplasms | 2 | 2019 | 118 | 0.340 |
Why?
|
Colorectal Surgery | 2 | 2020 | 114 | 0.330 |
Why?
|
Urinary Bladder Neoplasms | 5 | 2018 | 2094 | 0.320 |
Why?
|
Hyperthermia, Induced | 2 | 2021 | 365 | 0.320 |
Why?
|
Internship and Residency | 5 | 2018 | 5618 | 0.310 |
Why?
|
Treatment Refusal | 2 | 2020 | 421 | 0.300 |
Why?
|
Pancreatic Diseases | 1 | 2008 | 359 | 0.290 |
Why?
|
Operating Rooms | 2 | 2010 | 801 | 0.290 |
Why?
|
Nephrectomy | 2 | 2011 | 1001 | 0.290 |
Why?
|
Self Care | 1 | 2011 | 804 | 0.280 |
Why?
|
Colorectal Neoplasms | 6 | 2021 | 6575 | 0.280 |
Why?
|
Peritoneal Neoplasms | 2 | 2021 | 607 | 0.270 |
Why?
|
Clinical Clerkship | 1 | 2010 | 517 | 0.260 |
Why?
|
Colon | 2 | 2022 | 1767 | 0.260 |
Why?
|
Neuroendocrine Tumors | 2 | 2019 | 533 | 0.240 |
Why?
|
Colonic Neoplasms | 3 | 2020 | 2529 | 0.240 |
Why?
|
Pancreatectomy | 1 | 2008 | 852 | 0.240 |
Why?
|
Appendicitis | 2 | 2019 | 634 | 0.230 |
Why?
|
Graft Survival | 1 | 2012 | 3761 | 0.220 |
Why?
|
Kidney Neoplasms | 5 | 2017 | 4042 | 0.210 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2005 | 515 | 0.210 |
Why?
|
Retrospective Studies | 27 | 2021 | 72255 | 0.210 |
Why?
|
Carcinoma, Transitional Cell | 3 | 2018 | 769 | 0.200 |
Why?
|
Medical Staff, Hospital | 1 | 2005 | 628 | 0.200 |
Why?
|
Databases, Factual | 6 | 2021 | 7836 | 0.200 |
Why?
|
BCG Vaccine | 3 | 2018 | 358 | 0.200 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2021 | 4028 | 0.190 |
Why?
|
Duodenal Neoplasms | 1 | 2020 | 111 | 0.190 |
Why?
|
France | 2 | 2012 | 488 | 0.190 |
Why?
|
Follow-Up Studies | 17 | 2019 | 39285 | 0.190 |
Why?
|
Prostatitis | 1 | 1999 | 104 | 0.180 |
Why?
|
Sigmoidoscopy | 1 | 2019 | 154 | 0.180 |
Why?
|
Surgical Flaps | 2 | 2019 | 1634 | 0.180 |
Why?
|
Lymph Nodes | 3 | 2020 | 3433 | 0.180 |
Why?
|
Omentum | 1 | 2019 | 157 | 0.170 |
Why?
|
Carcinoma, Large Cell | 1 | 2019 | 114 | 0.170 |
Why?
|
Middle Aged | 40 | 2020 | 214871 | 0.170 |
Why?
|
Carcinoid Tumor | 1 | 2019 | 234 | 0.170 |
Why?
|
Intestinal Neoplasms | 1 | 2020 | 297 | 0.160 |
Why?
|
Kidney Transplantation | 1 | 2012 | 4139 | 0.160 |
Why?
|
Abdominal Abscess | 1 | 2018 | 146 | 0.160 |
Why?
|
Hematologic Neoplasms | 1 | 2008 | 1699 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 11317 | 0.150 |
Why?
|
Emotional Intelligence | 1 | 2018 | 140 | 0.150 |
Why?
|
Carcinoma, Small Cell | 1 | 2019 | 425 | 0.150 |
Why?
|
Adenocarcinoma | 7 | 2020 | 6371 | 0.150 |
Why?
|
Graft vs Host Disease | 1 | 2008 | 2824 | 0.150 |
Why?
|
Leiomyosarcoma | 1 | 2020 | 463 | 0.150 |
Why?
|
Humans | 57 | 2022 | 715124 | 0.150 |
Why?
|
Microwaves | 1 | 2017 | 176 | 0.150 |
Why?
|
Education, Medical, Graduate | 2 | 2005 | 2205 | 0.140 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2019 | 3555 | 0.140 |
Why?
|
Male | 42 | 2021 | 351081 | 0.140 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2019 | 483 | 0.140 |
Why?
|
Aged | 27 | 2020 | 162674 | 0.140 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 318 | 0.140 |
Why?
|
Mesothelioma | 1 | 2021 | 814 | 0.130 |
Why?
|
Clinical Competence | 2 | 2010 | 4646 | 0.130 |
Why?
|
Aged, 80 and over | 14 | 2020 | 58505 | 0.130 |
Why?
|
Endoscopy | 2 | 2022 | 1754 | 0.130 |
Why?
|
Personality | 1 | 2018 | 525 | 0.130 |
Why?
|
Cystectomy | 2 | 2018 | 627 | 0.130 |
Why?
|
Neoplasm Invasiveness | 4 | 2020 | 3702 | 0.130 |
Why?
|
Prognosis | 12 | 2020 | 29168 | 0.130 |
Why?
|
Healthcare Disparities | 2 | 2019 | 3027 | 0.120 |
Why?
|
Prolapse | 1 | 2013 | 59 | 0.120 |
Why?
|
United States | 11 | 2022 | 67665 | 0.120 |
Why?
|
Antidiarrheals | 1 | 2013 | 48 | 0.120 |
Why?
|
Abdomen | 1 | 2019 | 1101 | 0.120 |
Why?
|
Disease-Free Survival | 4 | 2019 | 7051 | 0.120 |
Why?
|
Hernia | 1 | 2013 | 67 | 0.120 |
Why?
|
Colostomy | 1 | 2013 | 97 | 0.120 |
Why?
|
Dermatitis, Contact | 1 | 2013 | 128 | 0.120 |
Why?
|
Ureteral Diseases | 1 | 2012 | 65 | 0.120 |
Why?
|
Quality of Life | 2 | 2011 | 11691 | 0.110 |
Why?
|
Female | 38 | 2021 | 377334 | 0.110 |
Why?
|
Surgical Wound Infection | 2 | 2019 | 1502 | 0.110 |
Why?
|
Pyoderma Gangrenosum | 1 | 2013 | 72 | 0.110 |
Why?
|
Combined Modality Therapy | 8 | 2021 | 8912 | 0.110 |
Why?
|
Ileostomy | 1 | 2013 | 121 | 0.110 |
Why?
|
Treatment Outcome | 12 | 2019 | 62186 | 0.110 |
Why?
|
Professional Competence | 1 | 2015 | 455 | 0.110 |
Why?
|
Career Choice | 1 | 2018 | 744 | 0.110 |
Why?
|
Urolithiasis | 1 | 2012 | 116 | 0.110 |
Why?
|
Lymphoma | 1 | 2020 | 1889 | 0.100 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2008 | 5153 | 0.100 |
Why?
|
Prostatectomy | 2 | 1999 | 1804 | 0.100 |
Why?
|
Ureteral Obstruction | 1 | 2012 | 300 | 0.100 |
Why?
|
Surgical Mesh | 1 | 2013 | 249 | 0.100 |
Why?
|
Carcinoma, Renal Cell | 2 | 2017 | 2964 | 0.090 |
Why?
|
Postoperative Complications | 5 | 2019 | 15098 | 0.090 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2011 | 235 | 0.090 |
Why?
|
Radiography, Interventional | 1 | 2017 | 1096 | 0.090 |
Why?
|
Diagnostic Self Evaluation | 1 | 2011 | 229 | 0.090 |
Why?
|
Hospitals, Community | 2 | 2021 | 336 | 0.090 |
Why?
|
Urinary Incontinence, Stress | 1 | 1991 | 172 | 0.090 |
Why?
|
Adult | 21 | 2019 | 212129 | 0.090 |
Why?
|
Vesico-Ureteral Reflux | 1 | 2012 | 422 | 0.090 |
Why?
|
Catheters, Indwelling | 1 | 2011 | 426 | 0.090 |
Why?
|
Urinary Incontinence | 1 | 2012 | 459 | 0.090 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2019 | 1164 | 0.090 |
Why?
|
Necrosis | 1 | 2012 | 1650 | 0.080 |
Why?
|
Incidence | 5 | 2021 | 20596 | 0.080 |
Why?
|
Sodium-Glucose Transporter 1 | 1 | 2008 | 115 | 0.080 |
Why?
|
Testicular Neoplasms | 1 | 1994 | 762 | 0.080 |
Why?
|
Health Status Disparities | 1 | 2019 | 1722 | 0.080 |
Why?
|
Laparoscopy | 1 | 2018 | 1990 | 0.080 |
Why?
|
Crohn Disease | 1 | 2020 | 2253 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2019 | 1890 | 0.080 |
Why?
|
Creatinine | 1 | 2012 | 1902 | 0.080 |
Why?
|
Survival Analysis | 3 | 2020 | 10531 | 0.080 |
Why?
|
Intestinal Absorption | 1 | 2008 | 435 | 0.080 |
Why?
|
Mucous Membrane | 1 | 2010 | 669 | 0.070 |
Why?
|
Vagina | 1 | 1991 | 776 | 0.070 |
Why?
|
Liver Neoplasms | 1 | 2021 | 4091 | 0.070 |
Why?
|
Suture Techniques | 1 | 1991 | 796 | 0.070 |
Why?
|
Medicaid | 1 | 2019 | 2621 | 0.070 |
Why?
|
Mitomycin | 2 | 2019 | 249 | 0.070 |
Why?
|
Sepsis | 1 | 2018 | 2474 | 0.070 |
Why?
|
Secondary Prevention | 1 | 2011 | 1509 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 2930 | 0.070 |
Why?
|
Faculty, Medical | 2 | 2010 | 1162 | 0.060 |
Why?
|
Catheter Ablation | 1 | 2017 | 2558 | 0.060 |
Why?
|
African Americans | 1 | 2019 | 5065 | 0.060 |
Why?
|
Risk Factors | 5 | 2019 | 70704 | 0.060 |
Why?
|
Intestine, Small | 2 | 2020 | 1230 | 0.060 |
Why?
|
Attitude of Health Personnel | 2 | 2010 | 3894 | 0.060 |
Why?
|
Reconstructive Surgical Procedures | 1 | 2016 | 2126 | 0.060 |
Why?
|
Ileum | 2 | 2020 | 564 | 0.060 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2019 | 680 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5010 | 0.050 |
Why?
|
Job Satisfaction | 1 | 2005 | 554 | 0.050 |
Why?
|
Cell Compartmentation | 1 | 2021 | 427 | 0.050 |
Why?
|
Time Factors | 3 | 2012 | 41081 | 0.050 |
Why?
|
Multivariate Analysis | 3 | 2019 | 12477 | 0.050 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 12404 | 0.050 |
Why?
|
Melanoma | 1 | 2018 | 5274 | 0.050 |
Why?
|
Leukocytosis | 1 | 2001 | 251 | 0.050 |
Why?
|
Urine | 1 | 2001 | 380 | 0.050 |
Why?
|
Age Factors | 4 | 2020 | 18789 | 0.040 |
Why?
|
Prostatic Neoplasms | 2 | 1999 | 10660 | 0.040 |
Why?
|
Biology | 1 | 2020 | 202 | 0.040 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2019 | 184 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2021 | 410 | 0.040 |
Why?
|
Surgical Wound Dehiscence | 1 | 2019 | 215 | 0.040 |
Why?
|
Acute Disease | 1 | 2008 | 7177 | 0.040 |
Why?
|
Hepatectomy | 1 | 2021 | 564 | 0.040 |
Why?
|
Students, Medical | 1 | 2010 | 1764 | 0.040 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2001 | 627 | 0.040 |
Why?
|
Chemokines | 1 | 2021 | 959 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2017 | 20398 | 0.040 |
Why?
|
Drug Therapy | 1 | 2020 | 519 | 0.040 |
Why?
|
Administration, Intravesical | 2 | 2010 | 70 | 0.040 |
Why?
|
Circadian Rhythm | 1 | 2008 | 2551 | 0.040 |
Why?
|
Myeloid Cells | 1 | 2021 | 789 | 0.040 |
Why?
|
Severity of Illness Index | 2 | 2008 | 16011 | 0.040 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2021 | 841 | 0.040 |
Why?
|
Glucose | 1 | 2008 | 4291 | 0.040 |
Why?
|
Stromal Cells | 1 | 2021 | 1358 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2021 | 23283 | 0.030 |
Why?
|
Length of Stay | 2 | 2019 | 6278 | 0.030 |
Why?
|
Thigh | 1 | 2016 | 231 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 970 | 0.030 |
Why?
|
Lithotripsy | 1 | 1995 | 140 | 0.030 |
Why?
|
Ureteral Calculi | 1 | 1995 | 103 | 0.030 |
Why?
|
Carcinoma in Situ | 1 | 2001 | 820 | 0.030 |
Why?
|
Prospective Studies | 5 | 2019 | 51181 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2005 | 2333 | 0.030 |
Why?
|
Canada | 1 | 2019 | 1947 | 0.030 |
Why?
|
Carcinoembryonic Antigen | 1 | 2015 | 350 | 0.030 |
Why?
|
Testicular Hydrocele | 1 | 1993 | 28 | 0.030 |
Why?
|
Seminoma | 1 | 1994 | 113 | 0.030 |
Why?
|
Antineoplastic Agents | 3 | 2010 | 13732 | 0.030 |
Why?
|
Sclerosing Solutions | 1 | 1993 | 75 | 0.030 |
Why?
|
Bleomycin | 1 | 1994 | 510 | 0.030 |
Why?
|
Propensity Score | 1 | 2020 | 1743 | 0.030 |
Why?
|
Age Distribution | 1 | 2019 | 2927 | 0.030 |
Why?
|
Adolescent | 4 | 2011 | 84999 | 0.030 |
Why?
|
Etoposide | 1 | 1994 | 627 | 0.030 |
Why?
|
Cohort Studies | 3 | 2021 | 39804 | 0.030 |
Why?
|
Vinblastine | 1 | 1994 | 509 | 0.030 |
Why?
|
Accreditation | 1 | 2015 | 446 | 0.030 |
Why?
|
Minocycline | 1 | 1993 | 154 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2019 | 1303 | 0.030 |
Why?
|
Orchiectomy | 1 | 1994 | 456 | 0.030 |
Why?
|
Endosonography | 1 | 2015 | 575 | 0.030 |
Why?
|
Minority Groups | 1 | 2019 | 1084 | 0.030 |
Why?
|
Monocytes | 1 | 2021 | 2661 | 0.030 |
Why?
|
Kidney Calculi | 1 | 1995 | 447 | 0.030 |
Why?
|
Algorithms | 1 | 2011 | 13669 | 0.030 |
Why?
|
Methods | 1 | 1991 | 1174 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2567 | 0.020 |
Why?
|
Colectomy | 1 | 2015 | 650 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 4916 | 0.020 |
Why?
|
Phlorhizin | 1 | 2008 | 39 | 0.020 |
Why?
|
Remission Induction | 1 | 1994 | 2389 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2021 | 3426 | 0.020 |
Why?
|
Neutrophils | 1 | 2021 | 3850 | 0.020 |
Why?
|
Lymph Node Excision | 1 | 1994 | 1198 | 0.020 |
Why?
|
Cisplatin | 1 | 1994 | 1663 | 0.020 |
Why?
|
Colonoscopy | 1 | 2015 | 1316 | 0.020 |
Why?
|
Insurance, Health | 1 | 2020 | 2496 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6779 | 0.020 |
Why?
|
Poverty | 1 | 2019 | 2577 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7947 | 0.020 |
Why?
|
Jejunum | 1 | 2008 | 503 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 2962 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10651 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2021 | 8674 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2021 | 16943 | 0.020 |
Why?
|
Patient Compliance | 1 | 2015 | 2753 | 0.020 |
Why?
|
Contrast Media | 1 | 2017 | 5270 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10379 | 0.020 |
Why?
|
Logistic Models | 1 | 2019 | 13594 | 0.020 |
Why?
|
Postoperative Care | 1 | 2010 | 1512 | 0.010 |
Why?
|
Calcinosis | 1 | 1991 | 1442 | 0.010 |
Why?
|
Gravity Sensing | 1 | 2001 | 4 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10082 | 0.010 |
Why?
|
Work Schedule Tolerance | 1 | 2005 | 564 | 0.010 |
Why?
|
Kidney Diseases | 1 | 1991 | 2128 | 0.010 |
Why?
|
Urography | 2 | 1991 | 326 | 0.010 |
Why?
|
Workload | 1 | 2005 | 859 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2005 | 3565 | 0.010 |
Why?
|
Leukocyte Count | 1 | 2001 | 1677 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2008 | 8602 | 0.010 |
Why?
|
Risk Assessment | 1 | 2018 | 23511 | 0.010 |
Why?
|
Forecasting | 1 | 2005 | 2944 | 0.010 |
Why?
|
Data Collection | 1 | 2005 | 3293 | 0.010 |
Why?
|
Angiography | 2 | 1991 | 1668 | 0.010 |
Why?
|
Administration, Intravaginal | 1 | 1993 | 143 | 0.010 |
Why?
|
ROC Curve | 1 | 2001 | 3526 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2008 | 13292 | 0.010 |
Why?
|
Injections, Intralesional | 1 | 1993 | 282 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2007 | 3950 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 7480 | 0.010 |
Why?
|
Cyproterone Acetate | 1 | 1991 | 7 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2005 | 3320 | 0.010 |
Why?
|
Rats | 1 | 2008 | 25090 | 0.010 |
Why?
|
Ultrasonography | 2 | 1995 | 5943 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 1997 | 20059 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2008 | 12425 | 0.010 |
Why?
|
Biopsy | 2 | 1991 | 6750 | 0.010 |
Why?
|
Mastectomy | 1 | 1997 | 1703 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 34394 | 0.010 |
Why?
|
Cell Nucleus | 1 | 1994 | 3016 | 0.000 |
Why?
|
Disease Progression | 1 | 2001 | 13302 | 0.000 |
Why?
|
Prostate-Specific Antigen | 1 | 1991 | 2274 | 0.000 |
Why?
|
Recurrence | 1 | 1993 | 8269 | 0.000 |
Why?
|
Animals | 1 | 2008 | 170726 | 0.000 |
Why?
|
Child | 1 | 1995 | 74146 | 0.000 |
Why?
|